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The enzyme catalase (EC1.11.1.6  hydrogen peroxide/ hydrogen peroxide oxidoreductase) 
was one of the earliest known and examined enzymes, and several of its unique characteristic 
features were described. A significant number of these features, however, could only be 
proved and explained later with the help of the most recent scientific methods. 
The 90s’ boom in molecular biology research followed by whole-genome sequencing first 
accomplished in 2000 gave a new impetus to research on catalase enzyme as well.  
The determination of the full sequence of catalase gene was a great help to researchers, 
including our own research team. It helped  us to map the coding and non-coding sequences in 
Hungarian populations, to detect mutations, polymorphisms and SNPs in catalase enzyme, 
and examine them in different diseases. My thesis advisor and his fellow researchers studied 
the reasons for decrease in catalase activity. Their research concentrated on the association of 
decrease in enzymatic activity detectable in different diseases and the catalase gene 
polymorphisms and mutations. I joined their research in 2008. 
We measured the activity of enzyme catalase in patients with the diseases like type 1, type 2 
and gestational diabetes, vitiligo, presbyacusis, microcytic anemia, and  beta-thalassemia. The 
samples with decreased activity were further examined with molecular biology methods  of 
PCR-SSCP, RFLP, heteroduplex analysis and  sequence analysis in search for the genetic 
reasons of decrease. We gained several interesting and valuable results, which were first 
presented in student thesis papers, Students’ Research Conference papers (TDK - Hungarian 
abbreviation), or at Hungarian and international conferences. Our novel results were 
published in international scientific journals. 
I have been working on the detection of polymorphisms of the gene encoding the catalase 
enzyme and the reasons for decreased enzymatic activity ever since. My thesis is a summary 
of the results I have gained since 2008. 
 
2. ENZYME CATALASE 
     Free radicals are being continuously produced as a result of oxidation-reduction 
biochemical processes in the human body. Oxidative stress occurs when the concentration of 
the reactive oxygen species (ROS) exceeds the antioxidant capacity of the body. The 
damaging effect of ROS is well-known in conditions like diabetes mellitus, atherosclerosis, 
chronic hepatic conditions, kidney failure, tumors, rheumatoid arthritis and neurodegenerative 
diseases. 
Reactive oxygen species are capable of damaging proteins, lipids and the DNA, which carries 
the genetic information of cells. A possible result of this damaging process can be the failure 
in membrane function, the formation of oxidized lipids, as well as mutations in DNA. 
Prolonged oxidative damage may cause the aging of cells and  could contribute to the 
development of chronic conditions and tumors. 
The second line of defense against damaging agents like hydrogen peroxide is provided by 
antioxidant enzymes such as superoxide-dismutase, glutathione-peroxidase and catalase.. By 
now catalase enzyme seems to be of the greatest importance in the hydrogen peroxide 
removal.  
     Catalase (EC 1.11.1.6, hydrogen peroxide/ hydrogen peroxide oxidoreductase) forms a 
tetramer composed of four identical subunits with a molecular weight of 240 kDa. The 
specialty of the substrate decomposition process is that the enzyme does not function if the 
concentration of H2O2 is physiological. 
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The decomposition of hydrogen peroxide is a two-step process. In the first step enzyme 
substrate complex I (compound I) is formed in a reversible reaction.  
In the second catalytic step complex I oxidizes a second hydrogen peroxide molecule forming 
oxygen and a molecule of water. 
     The blood cells contain the enzyme catalase in different concentrations with the highest in 
erythrocytes.  Moe than 99 % of blood catalase derives from erythrocytes. The reference 
mean for blood catalase activity is 113.3 MU/L of blood. If we relate it to 1 L of erythrocytes, 
the activity is 251.7 MU/L of erythrocytes. 
It could be assumed that the catalase found in high concentration in blood also has a general 
protective role against the hydrogen peroxide. Hydrogen peroxide could damage the tissues 
when the catalase concentration is low.  
The decreased activity of the enzyme can lead to early manifestation of several diseases like 
tumors, anemias, vitiligo, diabetes mellitus. 
     Acatalasemia is a disorder marked by congenital absence of catalase, which is a genetically 
mutant homozygous condition. For these patients the substrate measuring methods can still 
detect an activity of 1-8 %. Hypocatalasemia is the heterozygous condition and these patients 
are with about 50 % of the blood catalase. The decrease in enzymatic activity can also be 
related to the polymorphisms of catalase gene which could cause a decrease in protein 
expression.  
The first patient with acatalasemia was described by Professor Takahara in Japan in 1946. He 
observed almost total lack of hydrogen peroxide decomposition in an 11-year-old girl patient. 
To measure blood catalase activity, he applied the permanganometric titration of hydrogen 
peroxide and as a result, in 6 cases he could observe ”total” deficiency of catalase activity. In 
5 cases the activity was <10 %, and in 2 cases the activity was 10 %. Following the discovery 
made by Professor Takahara, acatalasemia came to be detected in further 12 countries, with 
the highest numbers in Japan (91) and Switzerland (11).  
The examination of a large Hungarian population (n=28,252) the acatalasemia has shown an 
incidence of 0.05/1000. Our research team detected the first acatalasemia cases in Hungary in 
1989 (4.6 MU/L). On the other hand, the incidence of hypocatalasemia in the Hungarian 
population is 0.18/1000. 
     Type 2 diabetes mellitus can be considered a complex condition. Its development is 
influenced by environmental and genetic factors alike. Several research teams include in their 
scope the assessment of the association between catalase deficiency and diabetes. In Hungary 
we carried out detailed examination on this topic. The studies performed so far have shown 
that one or more catalase gene mutations may contribute to the early manifestation of type 2 
diabetes mellitus. We found that in inherited catalase deficiency the diabetes is more frequent 
than in normocatalasemic subjects. We may suppose that the lack of catalase makes hydrogen 
peroxide concentration increase chronically, which will exert a damaging effect on the 
pancreatic beta-cells highly sensitive to oxidation.  
     In microcytic anemia the number and size of erythrocytes decreases. Red blood cells are 
smaller than physiological and their hemoglobin content is also lower, i.e. they are 
hypochromic.  
Genetic disorders may also lead to the formation of small hypochromic red blood cells. It is 
also genetic disorder that causes thalassemia, which can be divided in two main groups. In α-
thalassemia the hemoglobin α-chain fails to work sufficiently. In the more common β-
thalassemia the synthesis of the β-chain is decreased or deficient. The decreased blood 
catalase activity in these erythrocytes may lead to an increase in oxidative processes as the 
damaging and active H2O2 is not eliminated. The examination of the association between 
decreased blood catalase activities and β-thalassemia may lead to a better understanding of the 
disease pathology. 
   
4 
 
     Catalase protein is coded by a single gene, the catalase gene, which is located on the short 
arm of chromosome 11 at position 13. The gene spans 33,114 kb and has 13 exons and 12 
introns. Its chromosome location is chr:11:34,417,054-34,450,176. On the basis of the 
information available in the NCBI database, by the year 2012 there were 245 nucleotide 
positions detected in the catalase gene that were different from the consensus. The majority of 
polymorphisms result in a benign condition with no effect on enzymatic activity. They do not 
affect catalase protein expression, and it either has no pathological effect  or it has not yet 
been discovered. 
     Our research team has also been working for decades with the association between various 
diseases and the mutations, polymorphisms and SNP of the catalase gene. We could detect 
significant decrease in catalase activity in the presence of the T mutant allele and   we found 
that the C111T missense mutation  increases the susceptibility of vitiligo.  
The mapping of the exonal and intronal regions of the gene encoding the enzyme is still 
undergoing. The increase of molecular biology techniques made it possible to detect in the 
Hungarian population acatalasemia mutations. We named the detected mutations as the A, B, 
C, D, E types of the Hungarian acatalasemia.  Investigating the causes of acatalasemia and 
hypocatalasemia may help us get a better insight into the genetic and epigenetic factors 
influencing the activity of this enzyme. We may suppose the toxic effect of an increased 
hydrogen peroxide concentration in cells and tissues due to a decrease in catalase enzyme 
activity deriving from genetic abnormalities. The highly oxidative environment may favor for 
oxidative stress, which can further damage stress-sensitive organs and tissues. By examination 
of the catalase gene mutations we might get to a better understanding of pathology and 
possible treatment of several diseases. 
 
3. AIMS 
For my thesis entitled Examination of the association between catalase gene polymorphisms, 
mutations and catalase activity the aims are listed bellow. 
 
1. To examine with a simple mutation/polymorphism screening method the effect of 
polymorphism rs769217 in exon 9 on the activity of the enzyme catalase in microcytic anemia 
and beta-thalassemia patients. 
 
2. To examine the effects of polymorphisms of  rs769217 in exon 9 and rs1001179 in the 
promoter region on blood catalase activity, and on  lipid and carbohydrate biomarkers such as 
triglyceride, cholesterol, HDL, LDL, ApoA-I, ApoB, glucose, and HbA1c. 
 
3. To be sorted out a cohort with blood catalase activity lower than 50%. We may suppose 
that cataalse gene polymorphisms presumably more frequent in this group than in 
normocatalasemics. For this purpose, to examine the 13 exonal and 12 intronal regions to 
detect further mutations, polymorphisms and SNPs. The newly detected DNA polymorphisms 
and mutations may have an effect on blood catalase activity and could contribute to the 
pathology of several diseases.  
 
4. A further aim is to set up a control group with blood catalase activity within the reference 
range. The analysis of such samples would make it possible to perform comparative analysis 
of the catalase gene. 
 




4. MATERIALS AND METHODS 
4.1. Samples  
The blood samples (EDTA-treated full blood samples) were used during my research work. 
They were collected from the clinics (Internal Medicine, Pediatrics, Otorhinolaryngology) of 
the Medical and Health Science Center of University of Debrecen. The samples had been 
referred for laboratory analysis to the Clinical Biochemistry and Molecular Pathology 
Department (today’s Laboratory Medicine). The analysis only comprises the data of the 
patients whose blood hemoglobin concentration was in the reference range (above 120 g/L). 
 
4.2. Patients and controls 
During the examination of catalase gene exon 9: rs769217 polymorphism the samples of 98 
patients (microcytic anemia and beta-thalassemia patients) and 50 control samples were 
examined. 
The patient and control samples to be used for the analysis of catalase rs769217 and 
rs1001179 polymorphisms had been obtained from outpatients of the Diabetes Specialty Care 
of the Internal Medicine Department of the University, presented between 2007 and 2010.  
We measured blood catalase activity to screen a big number of patients (617) and controls 
(295) samples for the examination of novel acatalasemia mutations.  
The blood samples of controls were collected from staff members of the different clinics at  
the Clinical Center  (former  Medical and Health Science Center) of the University of 
Debrecen. These health care test samples were sent for analyses to the Department of the 
Laboratory Medicine.  The control cohort included subjects with blood catalase activity (80.3-
146.3 MU/L) and hemoglobin concentration (120-180 g/L) both within the reference range. 
The samples were assigned a code containing both numbers and letter to ensure anonymity. 
Our research had been approved by the Ethical Committee/Institutional Review Board  of the 
University of Debrecen with the authorization number 2734-2008. 
 
4.3. Measurement of catalase enzyme activity 
In order to determine catalase activity, I used a spectrophotometric assay, which measures the 
concentration of hydrogen peroxide substrate.  
Decomposition of hydrogen peroxide substrate was stopped after 60 seconds by adding 
ammonium molybdate. Ammonium molybdate forms a complex with the hydrogen peroxide 
stopping the enzymatic reaction. This complex of hydrogen peroxide and ammonium 
molybdate is yellow in color, and its absorbance is measured at 405 nm which is depends on 
the hydrogen peroxide concentration.  
 
4.4. Determination of lipid parameters and glucose concentration 
Lipid metabolism parameters (triglyceride, total cholesterol, HDL cholesterol, LDL 
cholesterol, ApoAI, ApoB) and glucose concentration were determined in serum with Roche 
Integra assays, Roche Integra 700, Modular P800 analyzer (Roche Diagnostics GmbH, 
Mannheim, Germany). 
 
4.5. Determination of hematological parameters 
Blood hemoglobin and mean cell volume (MCV) of red blood cells were measured with 
Sysmex XE 2011D hematological analyzer (Sysmex, Japan), while hemoglobin A2 and 
hemoglobin F were determined with a HPLC method, (Variant II instruments, Haemoglobin 
Testing System, BioRad, Hercules, CA, USA) from blood treated with anticoagulant EDTA. 
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The analyses were performed at the Division of Hematology and Separation Technique at the 
Department of Laboratory Medicine of  the University of Debrecen.  
 
4.6. Molecular biology techniques 
DNA isolation 
Genomic DNA was isolated from buffycoat (blood fraction rich in leucocytes) treated with 
anticoagulant EDTA using QIAmp Kit (DNA Blood Mini Kit, QIAGEN, Hilden, Germany). 
PCR  
For the PCR reaction the primers and steps recommended by Wen and Kishimoto were used 
in the amplification of exons. 
Electrophoresis 
The resulting PCR products were examined in 6 % polyacrylamide gel and visualized by 
silver staining.  The lengths of DNA fragments were compared to molecular weight markers. 
SSCP analysis 
The dsDNA was single-stranded by denaturation and immediately cooled on ice and analyzed 
by electrophoresis.  
PCR-RFLP analysis with enzyme BsTX1 
Restriction fragment length polymorphism analysis (RFLP) was performed with BsTXI 
restriction enzyme (Amersham Pharmacia Biotech UK, Buckinghamshire, England). The 
enzyme recognizes the CCANNNNN*NT**GG sequence and cuts the 238 bp long 
PCR product into two fragments of 153 bp and 85 bp length. 
DNA sequencing  
Purified PCR products (QIAquick PCR Purification Kit QAGEN, Hilden, Germany) were 
sequenced with Taq Dye-DeoxyTermination Cycle Sequencing Kit of 50 ul final volume 
(BigDye Term v.1.1 Cycle Sequencing kit, Applied Biosystems, Foster City, CA USA) and 
separated with capillary electrophoresis (3100-Avant, Genetic Analyzer, ABIPRISM, Applied 
Biosystems, Foster City, CA, USA). The sequencing reactions were performed at the Division 
of Molecular Genetics at the Department of Laboratory Medicine of the University of 
Debrecen.   
Heteroduplex analysis 
This mutation screening method is used for examination of the heterozygous states. The 
amplified DNA products were analyzed either with SURVEYOR Mutation Detection Kit 
(Transgenomic Ltd., Elancourt, France) or with the conventional method.  
The double-stranded DNA were heated and treated with surveyor nuclease. This enzyme 
recognizes and cleaves all types of mismatches arising from SNPs. DNA fragments were 
separated using 6 % polyacrylamide gel electrophoresis and visualized by silver staining.  
The conventional method includes the high temperature for formation of single strands from 
the double strands of DNA. After this step, the slow cooling could help the formation of 
heteroduplexes which could be detected by electrophoresis and silver staining. 
 
4.7. Statistical analysis 
For the evaluation of data Student’s t-test was used. For analysis of the genotype frequencies 
we used 3 x 2 contingency table, and for that of allele frequencies and odds ratio (OR) 2 x 2 
contingency table was used. The Hardy-Weinberg (H-W) equilibrium was estimated 
according to the χ2 test. Values of p below 0.05 were regarded as significant. 
 
 





5.1 Simple method for examination of catalase rs769217 polymorphism in exon 9 
PCR products of the 2, 3, 7, and 9 exons of the catalase gene were examined by 
polyacrylamide gel electrophoresis and silver staining. The electrophoretic patterns of exons 
2, 3, 7 showed the double-stranded PCR products in the 200 and 400 bp region. After 
denaturation the single-stranded DNA bands could be detected with a weaker intensity in the 
400-600 bp regions.  
For the exon 9 we got a different pattern when the step of denaturation was omitted. Double-
stranded DNA 238 bp length bands have a lower intensity and 400- 600 bp regions showed a 
highly stained and well separated one or two bands. For the identification of this phenomenon 
we performed the following experiments.  
1. Different DNA staining procedures of silver impregnation, SYBR Green II, and SYBR 
Green I were used. The bands appearing in the 400-600 bp region were only visualized 
by the single-stranded DNA (SYBR Green II) staining while the silver staining 
detected bands both regions. 
2. DNA sequence analyses of the samples with the newly detected bands were 
performed. The DNA sequence analysis of the samples was consistent with the 
electrophoretic pattern. In the 400-600bp region, the fast migrating band is the 
homozygous TT mutant, the slowly migrating is the homozygous CC wild. When both 
bands appear it can be identified as the CT heterozygous genotype. 
3. The simple method and the DNA sequencing yielded the same results for the 
genotypes in 74 samples. 
4. Evaluation of samples of 72 subjects with the SSCP (denaturing with formamide / 
sodium hydroxide at 940C for 6 minutes) and the simple method without denaturation 
yielded the same genetic types for every sample. The denaturation free pattern does 
not contain any further conformers than denatured samples that make it. 
5. During the treatment of PCR products with nuclear enzyme (SURVEYOR Mutation 
Detection Kit) the double stranded heteroduplex and single-stranded DNA are cut. 
After the cutting of the heterozygous mutant (CT genotype) and single stranded DNAs 
only the smaller (158bp) cutting product could be detected on the gel. 
6. PCR-RFLP analysis was also used as a further comparative test. PCR 
products were digested with BstX1 (Amersham Pharmacia Biotech UK, 
Buckinghamsshire, England) restriction enzyme. The restriction enzyme could 
recognize the CCANNNNN * NT ** GG sequence which can be found in the exon 9 
examined region. The two methods yielded the same genotypes. 
The C111T simple polymorphism detection method was investigated for the further known 
polymorphisms (C37T, G113A, G5) of exon 9 of the catalase gene. For the C37T, G113A and 
G5A polymorphisms, the method could not be a useful tool to identify the genotypes. 
Summarizing the results of 1-6 experiments, the spontaneously formed single-stranded DNA 
pattern without denaturation can be used to examine C111T polymorphism (rs769217, 
+22348) in exon 9 of the catalase gene. 
 
5.2  Examination of the rs769217 polymorphism of the catalase gene in Hungarian 
microcytic anemia, beta-thalassemia patients and control subjects 
The method showed in the previous chapter was used to examine the C111T polymorphism of 
exon 9 in the catalase gene. In this study, genotypes of 55 microcytic anemia, 43 beta-
thalassemia patients, and 50 controls were investigated and compared to European data. The 
C allele (71%) seems to be the same in the Hungarian control group and in European (80%) 
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individuals. There was no significant difference in the frequency of C alleles in microcytic 
anemia (67%, p=0.559) and beta-thalassemia (65%, p=0.265) when compared to the 
European control group.  
The genotype distribution in the European control group showed significant differences 
compared to the Hungarian microcytic anemia (p=0.0059) and beta-thalassemia (p=0.049). 
The blood-catalytic activity of the microcytic anemic group is lower than that of the 
Hungarian control group (p<0.025), similarly to those of the beta-thalassemia group and 
control group (p <0.016). Comparison of the catalase activity of the microcytic anemic CC 
genotype (89 ± 25 MU/L) with the TT genotype (64 ± 31MU/L) yielded a significant 
(p=0.005) decrease for the TT genotype.  
Compared with the TT genotype (75 ± 3 MU/L) of the CC genotype (92 ± 19 MU/L). a 
significant decrease (p=0.044) of blood catalase  was detected in  the beta-thalassemia 
patients.  
 
5.3 The effect of blood catalase polymorphisms of  rs769217 and rs1001179 on 
carbohydrate and lipid biomarkers in diabetes mellitus 
 
5.3.1. rs769217 (C111T in exon 9, + 22348C>T) polymorphism 
In the Hungarian diabetes and control group, the frequency of the C wild allele (68% and 
72%) was higher than that of the T mutant allele (28% and 32%). The TT homozygous mutant 
genotype (12%) was higher in type 1 diabetes mellitus than in type 2 (9%, p<0.02) and in the 
control group (9%, p<0.02). However, the catalase enzyme activity did not show any 
significant decrease for these cases. We found that there is a significant association between 
the genotypes and the age (CC: 45 ± 13 years, CT: 39 ± 14 years, TT: 36 ± 10 years, p <0.04).  
There were no significant differences in genotypes, lipid and carbohydrate parameters for type 
1 diabetic patients (p>0.08).  
In type 2 diabetes a significant decrease (p<0.001) was detected for the catalase activity in CC 
and CT genotype samples when they were compared either to those of the controls and  or to 
type 1 diabetics. In type 2 diabetes, a significant increase of glucose concentration was 
detected when the patients with the TT genotypes were compared to those with the CT 
genotypes (p<0.02). Furthermore, hemoglobin A1c (p<0.03) and ApoB (p<0.05) 
concentrations were higher for CT genotypes than those of CC genotype.  
 
5.3.2. rs1001179 (5’UTR region, – 262C/T) polymorphism 
For his polymorphism we found significant decrease in blood catalase activity in type 2 (91 ± 
20 MU/L, p<0.001) and in type 1 diabetes (95 ± 20 MU/L, p<0.048) compared to the control 
group (105 ± 17 MU/L). In type 1 diabetes, genotype analysis showed changes in blood 
catalase activity for CC (96 ± 26 MU/L) and CT (94 ± 30 MU/L ) compared to control (CC: 
109 ± 25 MU/L, CT: 102 ± 16 MU/L, p <0.05).  
In type 2 diabetes the blood catalase was found significantly decreased (p<0,05) for all three 
genotypes (CC: 98 ± 30 MU/L, CT: 88 ± 34 MU/L, TT: 84 ± 23 MU/L) compared to the 
control group (105 ± 17 MU/L). The greatest difference was detected for the TT genotype 
group (p <0.03) compared to the control group. 
There was a significant difference in genotypes of type 2 diabetes in carbohydrate biomarkers 
such as glucose (CC and TT, p <0.02), HbA1c (CC and TT, p <0.05) similarly to the lipid 
biomarkers of cholesterol (CC and TT, p <0.01), HDL (CC and TT, p <0.05), ApoB (CC and 
TT, p <0.05).  
No significant difference (p>0.1) was found between type 1, type 2 diabetics and the controls 
either for the genotypes or for alleles.  
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5.4 Screening program for new acatalasemia mutations  
Of 617 patients 51 subjects yielded blood catalase activity below 50% of the reference mean.  
These patients had diabetes mellitus (18, 35%), microcytic anemia (14, 27%), presbyacusis 
(10, 19.7%) and beta-thalassemia (4, 7.8%).  
In patients with decreased blood catalase 14 patients had decreased MCV (71 ± 10 fL, 
reference 89 ± 9 fL, p<0.0001) and decreased blood hemoglobin concentrations (129 ± 14 g / 
L, 134 ± 20 g /L, p>0.05). 
The mutation screening yielded 4 novel acatalasemia mutations in 7 patients. Based on these 
results, the novel acatalasemia mutations were named G1, H1, -2, and -3.  
More than half of the new mutations (4, 57%) were found in diabetic patients. Of the 4 
patients, three are type 2 and one with gestational diabetes. 
  
5.4.1. The novel acatalasemia mutations 
Four novel exon mutations were found in seven patients and the number of acatalasemia 
mutations increased from 11 to 15.  
The novel G1 type is caused by a C insertion in exon 2 (c. 106_107insC). This insertion 
causes a frame shift change from amino acid 35Gly to a TGA stop codon at position 70 
(p.G36Afs*5). This truncated catalase protein with its 70, instead of the 526, amino acids lack 
enzymatic function. 
The Arg127Tyr substitution (Type H1) may decrease the activity of catalase by changing the 
shape of the main channel and decreasing access of the substrate to the active center. This 
missense c.379C>T mutation was detected in one female patient with microcytic anemia and 
in another female with gestational diabetes mellitus. 
Type H2 is caused by a missense (c.390T>C) mutation with changing Arg129 to Leu. This 
mutation also could change the shape of the main channel of the catalase enzyme. 
The H3 (c.431A>T) type of Hungarian acatalasemia was detected in a hypocatalasemic 
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6. DISCUSSION AND SUMMARY 
     Examination of PCR products of catalase exon 9 with polyacrylamide gel electrophoresis 
revealed extra band(s) in the 400-800 bp range. The use of PCR-SSCP denaturation and 
specific staining technique with SybrGreen II, and nucleotide sequencing confirmed that the 
bands in question may be single-stranded DNAs. These bands located in the 400-800 bp range 
can be used to examine exon 9 polymorphisms. The highest level of sensitivity was detectable 
for the C111T polymorphism of exon 9 (rs769217). 
The method described by us is a simple, fast and cost-effective technique for genotype 
determination of C111T polymorphism in exon 9. 
     This method was used to examine the genotypes of C111T polymorphism in microcytic 
anemia and beta-thalassemia patients. 
Decreased blood catalase activity was observed in the case of the TT genotype of C111T 
polymorphism.  
The TT genotype of polymorphism C111T could be frequently detected (12%) in type 1 
diabetes. However, no significant changes were detected  in blood catalase activity, glucose, 
hemoglobin A1c, triglyceride, cholesterol, HDL, LDL, ApoA-I and APOB concentrations.  
On the other hand, in type 2 diabetes significantly decreased blood catalase was measured in 
the samples of CC and CT genotypes, accompanied by increased glucose, hemoglobin A1c 
and ApoB concentrations. 
     We examined the nucleotide polymorphism -262C>T (rs1001179) in the 5’ region which 
may play a role in regulatory processes. Decreased blood catalase activity could be detected in 
type 1 diabetics with CC and CT genotypes, as well as in type 2 diabetics with CC, CT, TT 
genotypes. The samples of type 2 diabetics with this polymorphism showed significant 
decreases when blood catalase activity, age and HDL concentration were measured. 
Furthermore, they showed an increase in glucose, hemoglobin A1c, cholesterol, and ApoB 
concentrations. 
      We set up a cohort comprising 51 patient samples for  which patients’ blood catalase 
activity was below 50% of the reference mean.  
Four novel acatalasemia mutations were detected, which increased the number of so-far 
known types of Hungarian acatalasemia from 11 to 15. Seven out of the 51 samples revealed 
four novel mutations belonging to samples in the type 2 diabetes and microcytic anemia 
cohorts. These results provide a new evidence for acatalasemia being a potential risk factor in 
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7. NEW RESULTS 
 
1. We examined the catalase gene exons for possible polymorphisms. The 
polyacrylamide gel electrophoresis of PCR product of catalase exon 9 yielded a new 
pattern. By using mutation screening methods (PCR-SSCP, single-strand and double-
strand DNA staining, nuclease digestion, PCR-RFLP) we could clearly demonstrate 
that conformational changes may result in single-stranded DNAs in the 400-800bp 
region.  
2. The bands seen in the electrophoretic pattern can be used for the detection of 
polymorphisms of catalase gene in exon 9. With the help of this simple, fast and cost-
effective technique polymorphisms can be determined without sequence analysis. 
3. The method developed by us could be used to detect C111T (rs769217) polymorphism 
and determine genotypes with very high efficiency.  
4. Further exon 9 polymorphisms (C37T, G113A, G5A) can also be detected using this 
method with a lower efficiency. For these nucleotide changes the genotypes could not 
be determined clearly. 
5. Our research group was the first to use the method we had validated to examine 
Hungarian microcytic anemia and beta-thalassemia patients as well as the Hungarian 
control group. Significantly lower blood catalase activity was detected in both 
microcytic anemia and beta-thalassemia samples of TT homozygous mutant genotype. 
6. The results of the two cohorts were compared to Hungarian controls, the European 
population and to data from the NCBI international database.  
Both cohorts (Hungarian microcytic anemic and beta-thalassemia patients) showed 
decreased blood catalase activity compared to the control group. 
7. We were the first to examine the association between polymorphism C111T and 
decreased blood catalase. 
8. Furthermore, it was our group to first perform a detailed analysis of the two known 
catalase gene polymorphisms (rs769217 and rs1001179) in type 1 and type 2 diabetes 
mellitus cohorts. 
9. Detailed comparative analysis was done on the effect of polymorphisms rs769217 and 
rs1001179 in the Hungarian control group and patients with type 1 and type 2 diabetes 
mellitus. 
10. We followed up on the change in 10 important diagnostic parameters (age, blood 
catalase, glucose, HgbA1c, triglyceride, cholesterol, HDL, LDL, ApoA-I, ApoB) in 
cohorts with type 1 and type 2 diabetes and the control group. 
The samples of the mutant (rs1001179 TT genotype) patients revealed decreased 
blood catalase activity accompanied by increased glucose and HbA1c concentrations. 
The same cohort showed increased cholesterol, HDL and ApoB concentrations. 
Associations were detected between type 2 diabetes and the TT mutant genotype of 
polymorphism rs1001179. 
11. We set up a cohort comprising 51 patients with their blood catalase below 50% of the 
reference mean. 
12. For these patients we examined all exons of the catalase gene. 
13. For seven patients four novel acatalasemia mutations were detected. 
14. These mutations are listed below.  
G1 type is caused by a C insertion in exon 2 (c. 106_107insC). 
The H1 type is caused by a missense c.379C>T mutation with Arg127Tyr substitution. 
Type H2 is caused by a missense (c.390T>C) mutation with changing Arg129 to Leu. 
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The H3 type has a nucleotide (c.431A>T) substitution which yields an Asp143Val 
amino acid change. 
15. The number of Hungarian acatalasemia mutations increased from 11 to 15. 
16. The novel acatalasemia mutations were detected in three microcytic anemia patients 
and four diabetics.  
These results suggest that the decreased blood catalase especially the increased 
hydrogen peroxide concentration due to the catalase deficiency may play a role in the 
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